Question 1

What are the expected benefits of participating in this trial compared to other treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma clinical trial (NCT03701022). Contact the study team or your healthcare provider for specific answers.

Question 2

What specific tests or procedures will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma clinical trial (NCT03701022). Contact the study team or your healthcare provider for specific answers.

Question 3

How often will I need to visit the clinic for treatment and evaluations?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma clinical trial (NCT03701022). Contact the study team or your healthcare provider for specific answers.

Question 4

What potential side effects should I be aware of with SHR-1210 and Apatinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma clinical trial (NCT03701022). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma clinical trial (NCT03701022). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma clinical trial (NCT03701022). Contact the study team or your healthcare provider for specific answers.

What this study is about